Ollin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedMC
Mubadala Capital
Activity from announced rounds
Activity in this selectionEnterprise software
Mubadala Capital is the investment manager whose official portfolio includes Ollin, Alloy, Juvena and Crusoe.
Recorded funding activity
Ollin develops retinal-disease antibodies. Alloy supplies discovery platforms and services, while Crusoe develops computing infrastructure. The manager remains separate from Mubadala Investment Company; the Precision Neuroscience relation stays in draft.
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $370M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionAlloy Therapeutics
Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners.
$40MSeries E
Role not disclosed